Forecast Evaluation Of High-sensitivity C-reactive Protein In Non-hodgkin Lymphoma

Objective：To evaluate the forecast of high-sensitivity C-reactiveprotein in non-Hodgkin lymphoma.Methods：We studied85consecutive patients with newly diagnosednon-Hodgkin lymphoma to determine the value of high-sensitivityC-reactive protein in comparison with known prognostic factors.Results：This high baseline high-sensitivity C-reactive protein group(≥4mg/L) was associated with inferior overall and progression-free survival(P=0.0013and P=0.0015, respectively) and remained a significantpredictor of overall and progression-free survival in multivariate Coxregression analysis (P <0.05). But the early-mid treatment serumhigh-sensitivity C-reactive protein level wasn’t an predictor of mortality inpatients with non-Hodgkin lymphoma (P>0.05).. This study suggests thatbaseline high-sensitivity C-reactive protein may serve as a usefulbiomarker to identify patients with NHL.Conclusion：The baseline high-sensitivity C-reactive protein can aprognostic parameter of survival as well as disease activity in patients with non-Hodgkin lymphoma.